Trial Watch: Phase II and Phase III attrition rates 2011–2012

  title={Trial Watch: Phase II and Phase III attrition rates 2011–2012},
  author={John Arrowsmith and P. Miller},
  journal={Nature Reviews Drug Discovery},
  • John Arrowsmith, P. Miller
  • Published 2013
  • Medicine
  • Nature Reviews Drug Discovery
  • Figures and Topics from this paper.

    Explore Further: Topics Discussed in This Paper

    Flexible Drug Approval Policies
    CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
    Novel methods for early phase clinical trials
    Drug Metabolism in Early Stage Drug Discovery and Drug Development
    Improved predictive models for pre-clinical drug toxicity studies
    A Bayesian paradigm for decision-making in proof-of-concept trials